HCW Biologics Inc.
HCWB
$4.99
-$0.27-5.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 24,133.33% | 73.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24,133.33% | 73.08% | |||
| Cost of Revenue | -48.61% | 72.80% | |||
| Gross Profit | 120,861.11% | 74.19% | |||
| SG&A Expenses | -48.98% | 90.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.71% | 50.82% | |||
| Operating Income | 165.21% | -50.72% | |||
| Income Before Tax | 428.74% | 115.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 382.83% | 115.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 382.83% | 115.79% | |||
| EBIT | 165.21% | -50.72% | |||
| EBITDA | 170.30% | -54.09% | |||
| EPS Basic | 135.70% | 49.17% | |||
| Normalized Basic EPS | 145.24% | 2.43% | |||
| EPS Diluted | 135.70% | 49.17% | |||
| Normalized Diluted EPS | 145.24% | 2.43% | |||
| Average Basic Shares Outstanding | 60.34% | 49.72% | |||
| Average Diluted Shares Outstanding | 60.34% | 49.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||